Ecuador in the Legal 500 Life Sciences Comparative Guide 2026

Meythaler & Zambrano Abogados
2 days ago
3 min read

Updated: 1 day ago

Meythaler & Zambrano Abogados contributed the Ecuador chapter to the third edition of the Legal 500 Life Sciences Comparative Guide, now published and available at no cost.

Why a comparative guide is useful

Legal 500 comparative guides answer the same questionnaire in every jurisdiction. That lets you set the Ecuadorian framework next to Germany, Brazil, Mexico, Japan or the United States and read the differences without rebuilding the context each time.

For a pharmaceutical, medical device or food company considering entering the market, the chapter is a starting point: which authority decides, what is required before marketing, and what obligations follow. For companies already operating here, it is a quick way to see where the rules have changed.

Authors: José Meythaler Baquero, Sebastián Meythaler Galarza and Karina Loza Santillán.

What the Ecuador chapter covers

Twenty-five questions on medicinal products, biologicals, medical devices, food and food supplements. The main areas:

Institutional framework. How responsibilities are divided among the Ministry of Public Health, ARCSA, ACESS, Agrocalidad and the National Council for the Setting and Review of Medicine Prices.
Product life cycle. From research through sanitary registration, and then to the obligations that continue once the product is on the market: variations, renewals, pharmacovigilance and technovigilance.
Clinical trials. Ethics committee approval, ARCSA authorization, the national registry, use of participant data and protection of undisclosed information.
Appealing a decision. What to do when a sanitary registration is denied: administrative remedies, time limits, and judicial review before the administrative courts.
Manufacturing and distribution. Operating permits, good manufacturing, storage and transport practices, and the conditions that apply along the distribution chain.
Pricing and public coverage. The three medicine pricing regimes and how supply to the public health system works.
Advertising and industrial property. The limits on promotion by product type, and the regime for pharmaceutical patents and trademarks, including enforcement before SENADI and border measures.
Liability. Administrative, civil and criminal exposure for products under sanitary control.
Digital health. When software with a medical purpose becomes a medical device, and what the use of artificial intelligence requires once it processes personal data.

The 2026 backdrop

The chapter was written in a busy year for Ecuadorian regulation. Four developments worth keeping in mind:

Medical devices. Resolution ARCSA-DE-2026-003-DASP, signed on 28 April 2026 and published in the Second Supplement to Official Register No. 286 of 18 May 2026, replaces the previous regime and takes effect nine months after signature, in January 2027. That leaves time to prepare.
Pharmacovigilance. Resolution ARCSA-DE-2025-052-DASP, published in Official Register No. 218 of 4 February 2026, replaces the rules governing the National Pharmacovigilance System and introduces coding under MedDRA and WHODrug.
Artificial intelligence and personal data. General Rule SPDP-SPD-2026-0009-R, of 12 February 2026, applies to anyone who develops, trains, implements, deploys or provides AI systems that process the data of Ecuadorian data subjects, wherever the system or the provider sits.
Cancer care. The Organic Law for the Comprehensive Care of Cancer, published in the Seventh Supplement to Official Register No. 236 of 4 March 2026, has been in force since publication; its implementing regulation is due within 180 days, by the end of August 2026.